CAR T-Cell Receptor Design for B-Cell Malignancy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CAR T-cell therapies for treating CD19+, CD20+, and CD22+ tumors and autoimmune diseases face challenges such as relapse due to short in vivo persistence, epitope masking, and off-tumor effects, along with risks of cytokine release syndrome and on-target off-tumor toxicity.
Innovation Solution
A novel CAR design with a short linker and long hinge, combined with a suicide gene like inducible caspase 9, enhances the recognition and elimination of unwanted CAR+ leukemia cells, even in high-leukemic contamination scenarios, while minimizing off-tumor targeting and providing a safety mechanism against toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CAR T-cell therapy is used to treat CD19+, CD20+, or CD22+ tumors, then anti-tumor activity is improved, but epitope masking occurs leading to reduced recognition of leukemic cells
Solution Approach 1:
The patent modifies the CAR structure by changing the linker length parameter (shorter linker) and hinge region length (longer hinge) to optimize the spatial arrangement of the antigen-binding domain, thereby maintaining recognition capability while enabling tumor cell lysis
2Reliability
If CAR T-cells are used to treat tumors, then complete remission rates are improved, but relapse occurs due to short in vivo persistence
Solution Approach 1:
The patent introduces dynamic control of CAR T-cell persistence through inducible suicide gene systems that allow temporary suppression when needed while enabling long-term persistence for sustained anti-tumor activity
3Productivity
If CAR T-cells are used to treat tumors, then tumor cell elimination is improved, but on-target off-tumor effects occur causing toxicity
Solution Approach 1:
The patent applies local quality control by making the CAR T-cell population heterogeneous - most cells maintain full anti-tumor activity while a subset carries inducible suicide genes that can be selectively activated to eliminate toxic cells without affecting overall therapeutic efficacy
4Reliability
If CAR T-cell therapy is administered, then initial remission is achieved, but cytokine release syndrome occurs causing life-threatening reactions
Solution Approach 1:
The patent implements feedback control through suicide gene systems that can be activated in response to cytokine release syndrome symptoms, allowing rapid termination of excessive T-cell activation and cytokine production to prevent life-threatening reactions
5Measurement precision
If standard CAR design is used, then antigen recognition is achieved, but CD19 antigen masking occurs reducing T-cell recognition
Solution Approach 1:
The patent optimizes the physical parameters of the CAR structure - specifically using a shorter linker and longer hinge configuration - to position the antigen-binding domain at an optimal distance and angle from the cell surface, preventing antigen masking while maintaining recognition precision
Data Source
AI summary
CAR T cells for treating CD19+, CD20+ OR CD22+ tumors, including leukemia and lymphoid malignances, provide increased safety in the therapy of the tumors and prevent epitope masking in CAR+ B-cell leukemia blasts. The CAR T cells decrease the potential risk of CD19−/CAR+, CD20−/CAR+ or CD22−/CAR+ leukemic relapse. In addition, the CAR T cells provide increased safety in the treatment of autoimmune diseases caused by B cells producing auto-antibodies.